DLA Piper — Life sciences in Belgium
Legal 500 ranks DLA Piper in Tier 2 for Belgium in Life sciences. This page sums up what that tier establishes, what it does not, and what you still need to check.
Legal 500 ranking
The tier shown here comes from the Legal 500 “Industry focus: Healthcare and life sciences” table for Belgium. We reproduce it unmodified: we do not yet run practitioner interviews, so we produce no hierarchy of our own. Within a tier, Legal 500 does not rank firms against each other; the display order there is ours, by number of Belgian areas recognised.
Beyond this area, Legal 500 lists DLA Piper in 27 Belgian practice areas: Aviation, Banking, finance and capital markets, Commercial, corporate and M&A, Competition: EU and global, Customs, trade, WTO and anti-dumping, Dispute resolution, EU regulatory: Chemicals, EU regulatory: Financial services, EU regulatory: Food, EU regulatory: Information technology, EU regulatory: Privacy and data protection, Employment, Environment, Fintech, Fraud and white-collar crime, Industry focus: Energy, Industry focus: Food, Industry focus: Healthcare and life sciences, Industry focus: IT and telecoms, Industry focus: Retail, Industry focus: Transport, Insolvency and restructuring, Insurance, Intellectual property, Private equity, Real estate and construction, Tax. Within the seven-area scope of this directory, the firm appears in 7.
- Tier
- Tier 2
- Source table
- Industry focus: Healthcare and life sciences
- Belgian areas recognised
- 27
What to check before instructing a firm in Life sciences
Identify your reference authority
The first filter is simple: does your file sit with the FAMHP, the NIHDI, the FASFC, or a European agency. A firm that deals with one of these desks daily knows its unwritten expectations, its real timelines and its people. That procedural knowledge is often worth more than theoretical mastery of the text.
Check how it works with your regulatory team
In this sector the lawyer works with your regulatory affairs team, not instead of it. Ask how the firm organises that interface, whether it produces advice your quality teams can use directly, and whether it can say where the legal question stops and the scientific decision begins.
Anticipate pricing and reimbursement
For a medicine, marketing authorisation is only half the road: without reimbursement, access to the Belgian market stays theoretical. If your product targets Belgium, check that the firm actually practises before the Drug Reimbursement Committee and handles managed entry agreements.
Check coverage of pharma patent litigation
Pharmaceutical patent disputes are a specialism within the specialism, with their own practitioners and procedural reflexes, particularly on supplementary protection certificates and interim measures ahead of a generic launch. If that is your subject, cross-reference this category with intellectual property.
Frequently asked questions
Is DLA Piper a recognised Life sciences firm in Belgium?
Yes. Legal 500 ranks DLA Piper in Tier 2 for Belgium in its “Industry focus: Healthcare and life sciences” table, which feeds the Life sciences area of this directory. That tier is Legal 500's, not ours: we reproduce it unmodified and we do not yet run our own interviews. It tells you the firm is recognised across a whole area; it does not tell you it is the right one for your matter, nor what it costs — we publish no rates and no verified client references.
Which other areas does DLA Piper appear in?
DLA Piper also appears in: Corporate & M&A, Intellectual property, Employment, ICT, digital & technology, Dispute resolution, Real estate, construction & environment. A firm ranked in several areas can handle a matter that spans two, which is common — an acquisition that triggers an employment workstream, a dispute that touches intellectual property. Its tier may differ from one area to another.